Global Adeno Associated Virus Vector Manufacturing Market Size to Exceed USD 6470.5 Million by 2035 | CAGR of 18.34%
Category: HealthcareGlobal Adeno Associated Virus Vector Manufacturing Market Size to Exceed USD 6470.5 Million by 2035
According to a Research Report Published by Spherical Insights & Consulting, The Global Adeno Associated Virus Vector Manufacturing Market Size is expected to Grow from USD 1015.5 Million in 2024 to USD 6470.5 Million by 2035, at a CAGR of 18.34% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Adeno Associated Virus Vector Manufacturing Market Size, Share, and COVID-19 Impact Analysis, By Scale of Operations (Clinical, Preclinical, and Commercial), By Therapeutic Area (Neurological Disorders, Metabolic Disorders, Ophthalmic Disorders, Muscular/Neuromuscular Disorders, and Others), By Application (Gene Therapy, Vaccine, Cell Therapy, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/adeno-associated-virus-vector-manufacturing-market
The adeno associated virus vector manufacturing market is the industry encompassing the production and purification of AAV vectors, which are used for delivering therapeutic genes for treating genetic disorders, neurological diseases, and other conditions in gene therapies and vaccines. Adeno-associated virus (AAV) is a non-enveloped virus that can be engineered to deliver DNA to target cells, and is considered one of the safest strategies for gene therapies due to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. An emergence of recombinant AAV-based gene therapy and advancements like integration of AI and machine learning in the AAV vector manufacturing are bolstering the market growth opportunities. The increasing prevalence of genetic disorders, along with an increasing emphasis on developing adeno-associated virus vectors for gene and cell therapy research and biomedical research funding, are driving the market. On the contrary, strict regulations, technical complexities, and increased operational costs related to cell & gene therapy manufacturing are challenging the market growth.
The clinical segment dominated the market with a major share of 47.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the scale of operations, the adeno associated virus vector manufacturing market is divided into clinical, preclinical, and commercial. Among these, the clinical segment dominated the market with a major share of 47.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Use of rAAV is being encouraged for therapeutic gene transfer to patients in a clinical setting. Further, its use in clinical trials, driving the demand for production and purification systems for generating a large amount of highly pure rAAV particles.
The neurological disorders segment dominated the adeno associated virus vector manufacturing market in 2024 and is anticipated to grow at a remarkable CAGR of 22.3% during the forecast period.
Based on the therapeutic area, the adeno associated virus vector manufacturing market is divided into neurological disorders, metabolic disorders, ophthalmic disorders, muscular/neuromuscular disorders, and others. Among these, the neurological disorders segment dominated the adeno associated virus vector manufacturing market in 2024 and is anticipated to grow at a remarkable CAGR of 22.3% during the forecast period. Some of the AAV-based drugs for neurological disorders include Upstaza, Luxturna, and Zolgensma. An increasing emphasis on addressing neurodegenerative diseases and genetic neurological disorders, is driving the demand for AAV vectors for targeted and precise interventions.
The vaccine segment accounted for the largest market share of 57.8% in 2024 and is anticipated to grow at a significant rate of 21.8% CAGR during the forecast period.
Based on the application, the adeno associated virus vector manufacturing market is divided into gene therapy, vaccine, cell therapy, and others. Among these, the vaccine segment accounted for the largest market share of 57.8% in 2024 and is anticipated to grow at a significant rate of 21.8% CAGR during the forecast period. AAV vectors are potentially used for gene vaccine delivery for both infectious and non-infectious diseases like influenza, COVID-19, Alzheimer's disease, and cancer, and works by delivering nucleic acid components encoded with the target protein for establishing an immune defense.
North America is expected to hold the majority share of the global adeno associated virus vector manufacturing market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of about 48.5% of the global adeno associated virus vector manufacturing market during the forecast period. United States is leading the North America adeno associated virus vector manufacturing market, driven by the prevalence of target diseases and the availability of funding for gene therapy development. An increasing strategic alliances in the pharma and biotech industries for promoting innovation, with the presence of the region’s advanced healthcare infrastructure, is responsible for driving the market.
Asia Pacific is anticipated to grow at the fastest pace with a 22.0% CAGR in the global adeno associated virus vector manufacturing market during the forecast period. China is leading the Asia Pacific adeno associated virus vector manufacturing market with a 20.8% CAGR, owing to the increasing implementation of AAV vectors as promising and popular tools for genetic medication. Gene therapy advancement, vaccine development, and innovation in cancer treatments, gene editing technologies, especially CRISPR, are promoting the market growth.
Major vendors in the global adeno associated virus vector manufacturing market are Oxford Biomedica PLC, GenScript (ProBio), Yposkesi, Inc., WuXi AppTec, Sarepta Therapeutics, Inc., Pfizer Inc., Roche, Audentes Therapeutics, BioMarin Pharmaceutical, F. Hoffmann-La Roche Ltd, Charles River Laboratories, Genezen, Creative Biogene, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In October 2025, Asimov launched its AAV Edge Stable producer system, intending to address the shortcomings of traditional transient transfection-based production and bring AAV manufacturing standards.
- In July 2025, ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, celebrated the opening of its facility in Hopewell, New Jersey. The facility would focus on the production of high-quality plasmid, lentiviral, and adeno-associated viral (AAV) vectors for genomic medicine.
- In August 2025, ProBio, a contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, announced the launch of current good manufacturing practice (cGMP) adeno associated virus (AVV) manufacturing services at its 128,000 sq ft facility in Hopewell, N.J. cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating, LLC, a subsidiary of National Resilience Holdco, Inc.
- In May 2025, CDMO 3PBIOVIAN officials reported that the company has launched the AAVion platform, a fully integrated adeno associated virus (AAV) manufacturing solution designed to accelerate gene therapy development.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the adeno associated virus vector manufacturing market based on the below-mentioned segments:
Global Adeno Associated Virus Vector Manufacturing Market, By Scale of Operations
- Clinical
- Preclinical
- Commercial
Global Adeno Associated Virus Vector Manufacturing Market, By Therapeutic Area
- Neurological Disorders
- Metabolic Disorders
- Ophthalmic Disorders
- Muscular/Neuromuscular Disorders
- Others
Global Adeno Associated Virus Vector Manufacturing Market, By Application
- Gene Therapy
- Vaccine
- Cell Therapy
- Others
Global Adeno Associated Virus Vector Manufacturing Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?